Pentwater Capital Management’s AstraZeneca AZN Stock Holding History

Pentwater Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-330,000	Closed	-$23.6M	–	151
2014 Q3	$23.6M	Sell	330,000 -1,260,000	-79%	-$92.2M	0.23%	71
2014 Q2	$118M	Buy	+1,590,000	New	+$115M	1.25%	22

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Pentwater Capital Management's AZN Position: Q3 2014 in Review

Pentwater Capital Management sold out of AstraZeneca (AZN) in Q3 2014, closing a stake of 50,256 shares — an estimated $3.68M sold.

Pentwater Capital Management first reported a position in AZN in Q2 2014 and held it in 1 quarter. The position peaked at $3.73M in Q2 2014. 401 funds tracked by Wall St. Rank hold AZN as of Q3 2014.

Pentwater Capital Management reported no remaining AstraZeneca position as of Q3 2014 after selling out during the quarter.
Pentwater Capital Management sold 50,256 AstraZeneca shares in Q3 2014, an estimated $3.68M.
Pentwater Capital Management first reported a position in AstraZeneca in Q2 2014 and held it in 1 quarter.
Pentwater Capital Management's AstraZeneca position peaked at $3.73M in Q2 2014.
401 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.

Based on Pentwater Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.